[1]张恒耀 纪少秀 汪燕燕 魏彦宁 颜青 毕然 党毓起.开郁苦泄法治疗气郁痰阻型新诊断超重2型糖尿病临床研究[J].陕西中医药大学学报,2023,(01):048-54.[doi:2096-1340(2023)01-0048-07]
 ZHANG Hengyao JI Shaoxiu WANG YanyanWEI Yanning YAN Qing BI Ran DANGYuqi.Clinical Observation on Treatment of New Onset of OverweightType 2 diabetes with Qi Stagnation and PhlegmObstruction by Kaiyu Kuxie Method[J].Journal of Shaanxi University of Traditional Chinese Medicine,2023,(01):048-54.[doi:2096-1340(2023)01-0048-07]
点击复制

开郁苦泄法治疗气郁痰阻型新诊断超重2型糖尿病临床研究
分享到:

《陕西中医药大学学报》[ISSN:2096-1340/CN:61-1501/R]

卷:
期数:
2023年01期
页码:
048-54
栏目:
出版日期:
2023-01-20

文章信息/Info

Title:
Clinical Observation on Treatment of New Onset of Overweight Type 2 diabetes with Qi Stagnation and Phlegm Obstruction by Kaiyu Kuxie Method
文章编号:
10.13424/j.cnki.jsctcm.2023.01.010
作者:
张恒耀12 纪少秀1 汪燕燕12 魏彦宁12 颜青12 毕然2 党毓起12
1.银川市中医医院,宁夏 银川 750001;
2.宁夏代谢性疾病(中西医结合) 临床医学研究中心,宁夏 银川 750001
Author(s):
ZHANG Hengyao12 JI Shaoxiu1 WANG Yanyan12 WEI Yanning12 YAN Qing12 BI Ran2 DANGYuqi12
1.Yinchuan Traditional Chinese Medicine Hospital,Yinchuan 750001,China;
2.Ningxia Metabolic Disease (Integrated Traditional and Western Medicine) Clinical Medical Research Center,Yinchuan 750001,China
关键词:
关键词:开郁苦泄超重新诊断2型糖尿病气郁痰阻中医治疗
Keywords:
Key words:Kaiku KuxieOverweightNew type 2 diabetesQi stagnation and phlegm obstructionTCM treatment
分类号:
R255.4
DOI:
2096-1340(2023)01-0048-07
文献标志码:
A
摘要:
摘 要:目的 评价开郁苦泄法治疗气郁痰阻型新诊断超重2型糖尿病患者的临床疗效。方法 研究纳入新诊断2型糖尿患者100例,随机分为治疗组和对照组各50例,在生活方式干预下,治疗组口服甘松降糖颗粒9 g/次,3次/日,对照组口服二甲双胍500 mg/次,3次/日,共观察12周,记录两组血糖、HbA1c、HOMA指数及脂代谢指标等统计分析。结果 (1)研究完成可评价样本83例,治疗组43例,对照组40例,治疗组和对照组HbA1c分别下降1.14%和1.34%,FBG降低1.93 mmol·L-1和2.23 mmol·L-1,2 h BG降低5.72 mmol·L-1和6.56 mmol·L-1,组内比较差异均有统计学意义(P<0.01),组间比较差异无统计学意义(P>0.05)。(2)胰岛素释放试验结果显示两组各时段血糖均较前明显下降(P<0.05),且1 h PG治疗组下降优于对照组(P<0.05),治疗组1 h INS升高优于对照组(P<0.05),两组3 h INS均较前降低(P<0.05),组间比较差异无统计学意义(P>005)。(3)两组治疗后体重、腰围、BMI下降均有统计学意义(P<0.01),治疗组TC和对照组LDL-C下降有统计学意义(P<005),组间比较差异均无统计学意义(P>0.05)。(4)两组HOMAIR和ISI均明显改善(P<0.01),组间比较无差异(P>0.05),两组HOMAβ较治疗前变化无统计学意义(P>0.05),但组间比较治疗组改善优于对照组(P<0.01)。(5)两组证候疗效比较治疗组总有效率90.70%,对照组77.50%,治疗组明显优于对照组(P<0.01)。结论 开郁苦泄法治疗新诊断超重2型糖尿病(气郁痰阻型)在控制血糖、减轻体重、改善胰岛素抵抗、调节血脂方面疗效与二甲双胍相当,并能显著改善患者中医证候。
Abstract:
Abstract:Objective To evaluate the clinical efficacy of the method of Kaiyu Kuxie in the treatment of newly overweight type 2 diabetes patients with Qi stagnation and phlegm stagnation.Methods 100 newly diagnosed type 2 diabetes patients were enrolled in the study,and randomly divided into the treatment group and the control group,50 patients in each group.Under the intervention of lifestyle,the treatment group took orally the Gansong Jiangtang Granules 9 g/time,3 times/day,and the control group took orally the metformin 500 mg/time,3 times/day.A total of 12 weeks were observed,and the blood glucose,HbA1c,HOMA index and lipid metabolism indexes of the two groups were recorded for statistical analysis.Results (1) There were 83 evaluable samples after the study,43 in the treatment group and 40 in the control group.HbA1c in the treatment group and the control group decreased by 1.14% and 1.34%,FBG decreased by 1.93mmol·L-1 and 2.23 mmol·L-1,and BG decreased by 5.72 mmol·L-1 and 6.56mmol/L at 2h.There were significant differences within the group (P<0.01),but no significant differences between the groups (P>0.05).(2) The results of insulin release test showed that the blood glucose of the two groups in each period was significantly lower than before (P<0.05),and the decrease in the 1h PG treatment group was better than that in the control group (P<0.05),the increase in the 1h INS of the treatment group was better than that in the control group (P<0.05),and the 3h INS of the two groups was lower than before (P<0.05),and there was no significant difference between the two groups (P>0.05).(3) The weight,waist circumference and BMI of the two groups decreased significantly after treatment (P<0.01).The decrease of LDL-C in the treatment group and the control group was statistically significant (P<0.05),and there was no significant difference between the two groups (P>0.05).(4) HOMA-IR and ISI in the two groups were significantly improved (P<0.01),and there was no difference between the two groups (P>0.05).HOMA-β in the two groups had no significant change compared with that before treatment (P>0.05),but the improvement in the treatment group was better than that in the control group (P<0.01).(5) The total effective rate of the treatment group was 90.70%,while that of the control group was 77.50%.The treatment group was significantly better than the control group (P<0.01). Conclusion The method of Kaiyu Kuxie in the treatment of newly diagnosed overweight type 2 diabetes (type of Qi stagnation and phlegm stagnation) is equivalent to metformin in controlling blood sugar,reducing weight,improving insulin resistance,and regulating blood lipids,and can significantly improve the TCM syndromes of patients.Abstract:Objective To evaluate the clinical efficacy of the method of Kaiyu Kuxie in the treatment of newly overweight type 2 diabetes patients with Qi stagnation and phlegm stagnation.Methods 100 newly diagnosed type 2 diabetes patients were enrolled in the study,and randomly divided into the treatment group and the control group,50 patients in each group.Under the intervention of lifestyle,the treatment group took orally the Gansong Jiangtang Granules 9 g/time,3 times/day,and the control group took orally the metformin 500 mg/time,3 times/day.A total of 12 weeks were observed,and the blood glucose,HbA1c,HOMA index and lipid metabolism indexes of the two groups were recorded for statistical analysis.Results (1) There were 83 evaluable samples after the study,43 in the treatment group and 40 in the control group.HbA1c in the treatment group and the control group decreased by 1.14% and 1.34%,FBG decreased by 1.93mmol·L-1 and 2.23 mmol·L-1,and BG decreased by 5.72 mmol·L-1 and 6.56mmol/L at 2h.There were significant differences within the group (P<0.01),but no significant differences between the groups (P>0.05).(2) The results of insulin release test showed that the blood glucose of the two groups in each period was significantly lower than before (P<0.05),and the decrease in the 1h PG treatment group was better than that in the control group (P<0.05),the increase in the 1h INS of the treatment group was better than that in the control group (P<0.05),and the 3h INS of the two groups was lower than before (P<0.05),and there was no significant difference between the two groups (P>0.05).(3) The weight,waist circumference and BMI of the two groups decreased significantly after treatment (P<001).The decrease of LDLC in the treatment group and the control group was statistically significant (P<0.05),and there was no significant difference between the two groups (P>0.05).(4) HOMAIR and ISI in the two groups were significantly improved (P<0.01),and there was no difference between the two groups (P>0.05).HOMAβ in the two groups had no significant change compared with that before treatment (P>0.05),but the improvement in the treatment group was better than that in the control group (P<0.01).(5) The total effective rate of the treatment group was 9070%,while that of the control group was 77.50%.The treatment group was significantly better than the control group (P<0.01). Conclusion The method of Kaiyu Kuxie in the treatment of newly diagnosed overweight type 2 diabetes (type of Qi stagnation and phlegm stagnation) is equivalent to metformin in controlling blood sugar,reducing weight,improving insulin resistance,and regulating blood lipids,and can significantly improve the TCM syndromes of patients.

参考文献/References:

[1]Li Y,Teng D,Shi X,et al.Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study[J].BMJ,2020,369:997.
[2]中华医学会糖尿病分会.中国2型糖尿病防治指南(2017版)[J].中华糖尿病杂志,2018,10(1):4-67.
[3]仝小林,刘喜明,魏军平,等.糖尿病中医防治指南[J].中国中医药现代远程教育,2011,9(4):148-151.
[4]王静,张进军,金虹,等.“六郁”论治肥胖[J].陕西中医药大学学报,2021,44(3):45-48.
[5]纪少秀,张恒耀,刘永家.从气病论治代谢综合征探讨[J].山西中医,2014,30(3):1-3.
[6]杨晓燕,宋宗良,杨伟钦.黄连越鞠丸联合生活方式干预糖尿病前期的临床研究[J].现代中医药,2011,31(2):25-27.
[7]王明坤,张珊珊.结合辨体论治谈2型糖尿病从湿热论治[J].现代中医药,2012,32(1):71-72.
[8]牛阳.《回回药方》研究[M].银川:阳光出版社,2010:311.
[9]王震,崔刚,孙理军.谈痰湿体质糖尿病的发病机理及治疗思路[J].现代中医药,2010,30(4):57-58.
[10] Rehman T,Ahmad S.Nardostachys chinensis Batalin:A review of traditional uses,phytochemistry,and pharmacology[J].Phytother Res,2019,33(10):2622-2648.
[11]胡明娟,唐榆,冯盏盏,等.甘松化学成分的研究[J]中成药,2019,41(7):1597-1601.
[12]袁玲,李静远,黄秀兰.回回甘松饮对糖尿病肾病大鼠肾脏保护作用的实验研究[J].北京中医药,2013,32(11):873-875.
[13]张义伟,董琳.回药甘松丸子对糖尿病治疗作用的实验研究[J].宁夏医学杂志,2011,33(12):1141-1142.
[14]AShrafizadeh M,Fekri HS,Ahmadi Z,et al.Therapeutic and biological activities of berberine:The involvement of Nrf2signaling pathway[J].Cell Biochem,2020,121(2):1575-1585.
[15]Feng R,Zhao ZX,Ma SR,et al.Gut Microbiotaregulated pharmacokinetics of berberine and active Metabolites in Beagle dogs after oral administration[J].Front Pharmacol,2018,9:214.
[16]赵亚丽.黄连素通过miR204/SIRT1改善糖尿病胰岛β细胞功能损伤的作用机制研究[D].长春:吉林大学,2019.
[17]Zhao Z,Li M,Li C,et al.Dietary preferences and diabetic risk in China:A largescale nationwide Internet databased study[J].J Diabetes,2020,12(4):270-278.
[18]柳红芳,郭清华,盛益华,等.胰岛素短期强化联合辛开苦降方治疗初发2型糖尿病的临床研究[J].中国医药导报,2010,7(8):18-20.
[19]赵昱,周丽波,董柳,等.辛开苦降法治疗肥胖2型糖尿病的临床研究[J].中华中医药学刊,2007,25(12):2575-2578.
[20]张艳红,张先慧,胡照娟,等.辛开苦降方对初发2型糖尿病KKay小鼠肝脏IRS2/PI3K通路的影响[J].世界中西医结合杂志,2013,8(11):1099-1102,1106.
[21]陈彦旭,金智生,何流,等.基于肠道菌群失调探讨辛开苦降法治疗糖尿病胃轻瘫[J].中国中医药信息杂志,2021,28(5):8-11.
[22]倪青,杜立娟,孟祥,等.半夏泻心汤对初诊2型糖尿患者血浆GLP-1的影响初探[J].北京中医药,2017,36(6):549-551.
[23]闫镛,庞国明,苗明三,等.黄连降糖片治疗2型糖尿病模型大鼠的量效关系研究[J].时珍国医国药,2018,29(3):562-565.

相似文献/References:

[1]张恒耀 纪少秀 汪燕燕 魏彦宁 颜青 毕然 党毓起.开郁苦泄法治疗气郁痰阻型新诊断超重2型糖尿病临床研究[J].陕西中医药大学学报,2023,(01):048.[doi:2096-1340(2023)01-0048-07]
 ZHANG Hengyao JI Shaoxiu WANG YanyanWEI Yanning YAN Qing BI Ran DANGYuqi.Clinical Observation on Treatment of New Onset of OverweightType 2 diabetes with Qi Stagnation and PhlegmObstruction by Kaiyu Kuxie Method[J].Journal of Shaanxi University of Traditional Chinese Medicine,2023,(01):048.[doi:2096-1340(2023)01-0048-07]

备注/Memo

备注/Memo:
基金项目:宁夏自然科学基金项目(2019AAC03280);宁夏青年科技人才托举工程项目(TJGC2019097);银川市科技创新重点专项(2021-SF-002)
更新日期/Last Update: 2023-02-20